News Archive

FREDERICK, Md., September 26, 2023: Today, Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded through the DOD’s Peer Reviewed Medical Research Program (PRMRP), the award recognizes the scientific merit of Theradaptive’s work in targeted regenerative therapeutics to create safer and more efficacious treatments for patients with conditions such as spinal degenerative disc disease, orthopedic trauma, and craniomaxillofacial and dental repair.

The Clinical Trial Award is aimed at providing assistance to companies implementing clinical trials for biologics or medical devices focused on improving the patient outcomes of military service members and veterans. This award will help Theradaptive scale up the production of its OsteoAdapt regenerative therapeutic product for spine and trauma repair and will become clinically available upon initiation of first in human clinical trials in early 2024.

The latest upgrade is part of wider goals to create the industry’s first unified digital data platform for decentralized and hybrid trials

ROCKVILLE, Md., Sept. 27, 2023 /PRNewswire/ — Emmes, a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces the addition of telehealth capabilities within Advantage eClinical. The new application means any scheduled visit can become virtual with video calls augmented directly through the platform and patients signing in through their existing participant portal. Advantage eClinical is designed to enable a simple, intuitive experience that fits seamlessly into the everyday lives of study participants and sites.

The BioHealth Capital Region continued its tradition of fostering innovation, collaboration, and growth in the life sciences sector with its series of events in 2023. The highlights included the 9th Annual BioHealth Capital Region Forum, the 8th Annual BioHealth Capital Region Crab Trap, and the 6th Annual BioHealth Capital Region Investment Conference, bringing together industry, academic, government, entrepreneurs, and investors.

Virginia Bio’s Women Building Bio Conference celebrates the contribution of women to the life sciences in the Commonwealth and beyond. The 8th annual conference theme, Building Better, will prompt us to explore how life sciences contribute to building a better future and highlight the increasingly significant role of women in it.

Opening – Technical Writer and Project Manager

BioHealth Innovation (BHI) is an innovation intermediary that facilitates commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia).

BHI is seeking a Technical Writer and Project Manager to join its team remotely. This position provides the opportunity to leverage scientific knowledge to evaluate the commercial potential of emerging technologies and provide recommendations on go-to-market strategies. This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals. This position is geared toward an early-career scientist with extensive writing experience and a history of funded grant proposals.

This position could be either employee or part time contractor depending on applicants experience and availability. Compensation will be competitive but dependent based on experience.

COLUMBIA, Md. (September 25, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 investment into Natáur. This recent investment came from TEDCO’s Social Impact Funds.

“Natáur is creating bio-based taurine—an essential nutrient for brain development, healthy aging, heart health, and microbiome balance,” said Kathleen Turano, Natáur CEO. “Taurine occurs naturally in animal products but it is missing in plants. With shifts towards more plant-based diets, taurine will need to be added as an ingredient or taken as a supplement to maintain healthy taurine levels. With TEDCO’s investment, we move closer to launching our bio-based taurine.”

WASHINGTON, Sept. 20, 2023 /PRNewswire/ — VerImmune Inc. (“VerImmune”), an early-stage biotechnology company specializing in the development of innovative products based on a novel Virus-inspired Particle (ViP™) technology platform, announced today the securing of an additional $3.125 million from follow-on Seed financing and a partnership milestone payment.

The follow-on financing was led by previous investor, Proxima VC, a specialist seed-to-growth healthcare venture capital firm with participation from other previous investors such as Gaingels, Mana Ventures and others. In addition to this financing, a milestone payment from Fosun Pharma USA was triggered by  the successful completion of a process development milestone.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.

United Therapeutics’ organ manufacturing efforts consist of seven investigational programs: xenoheart, xenokidney, xenothymokidney, regenerative lungs, 3D-printed lungs, 3D-printed livers, and 3D-printed kidneys. These groundbreaking programs are intended to address the ongoing shortage of transplantable organs for patients with end stage organ disease.